Bone marrow inflammation in haematological malignancies
Open accessThe DOI matches its Crossref record; 233 of the 238 references it cites were found in a registry or an index.
Abstract
Tissue inflammation is a hallmark of tumour microenvironments. In the bone marrow, tumour-associated inflammation impacts normal niches for haematopoietic progenitor cells and mature immune cells and supports the outgrowth and survival of malignant cells residing in these niche compartments. This Review provides an overview of our current understanding of inflammatory changes in the bone marrow microenvironment of myeloid and lymphoid malignancies, using acute myeloid leukaemia and multiple myeloma as examples and highlights unique and shared features of inflammation in niches for progenitor cells and plasma cells. Importantly, inflammation exerts profoundly different effects on normal bone marrow niches in these malignancies, and we provide context for possible drivers of these divergent effects. We explore the role of tumour cells in inflammatory changes, as well as the role of cellular constituents of normal bone marrow niches, including myeloid cells and stromal cells. Integrating knowledge of disease-specific dynamics of malignancy-associated bone marrow inflammation will provide a necessary framework for future targeting of these processes to improve patient outcome.
Overview
CoChat Summary
TL;DR
This review summarizes how inflammation in the bone marrow microenvironment shapes myeloid and lymphoid haematological malignancies. Using acute myeloid leukaemia and multiple myeloma as examples, it argues that inflammation has disease-specific and sometimes divergent effects on normal bone marrow niches and malignant cell survival.
Key findings
- Bone marrow inflammation is presented as a hallmark of tumour-associated microenvironments that affects niches for haematopoietic progenitor cells and mature immune cells, and supports malignant cell outgrowth and survival.
- The review focuses on inflammatory changes in myeloid and lymphoid malignancies, especially acute myeloid leukaemia and multiple myeloma, and highlights both unique and shared features of inflammation in progenitor-cell and plasma-cell niches.
- The authors state that inflammation exerts “profoundly different effects” on normal bone marrow niches in these malignancies and discuss possible drivers of these divergent effects.
- The review examines contributions from tumour cells, myeloid cells, and stromal cells to inflammatory changes in the bone marrow microenvironment.
Methods
- Narrative review article published in *Nature Reviews Immunology* (2024), not an original experimental study.
- Synthesizes prior literature on bone marrow inflammation in haematological malignancies, using acute myeloid leukaemia and multiple myeloma as illustrative examples.
- Main approach is conceptual synthesis and comparison of disease-specific dynamics of inflammation in normal and malignant bone marrow niches.
Limitations
- Not stated in the paper.
- Evident from the text: this is a review, so it does not report new primary data, sample size, or statistical analysis.
- Evident from the text: the abstract frames conclusions broadly, but the provided text does not specify detailed evidence grading or systematic review methods.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 3 Own results and interpretations
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, inflammation exerts profoundly different effects on normal bone marrow niches in these malignancies”
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the bone marrow, tumour-associated inflammation impacts normal niches for haematopoietic progenitor cells and mature immune cells”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“supports the outgrowth and survival of malignant cells residing in these niche compartments”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 1
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · cited 1×
“This is partly owing to genetic abnormalities that actively derail progenitor differentiation and partly owing to the previously discussed disruption of normal HSPC niches 34,68 , contributing to neutropenia and monocytopenia 69 .”
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · cited 2×
“Most mutations are in genes encoding transcription factors, epigenetic modifiers, spliceosome proteins or activators of signalling pathways 192 .”
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 1×
“CHIP is common, affecting approximately 10–15% of individuals over 70 years old, and is associated with an increased risk for cardiovascular disease and myeloid malignancies 150,151 .”
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863 · cited 1×
“In these conditions, stromal cells can adopt distinct inflammatory phenotypes and functions in response to inflammation or damage-associated stimuli 31 .”
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806 · cited 1×
“…is not without precedent, as several solid cancers are infiltrated by activated innate immune cells that contribute to tumorigenesis and tumour progression through the secretion of pro-inflammatory cytokines, production of reactive oxygen species, immune suppression and release of metabolites 67 .”
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · cited 1×
“CHIP is common, affecting approximately 10–15% of individuals over 70 years old, and is associated with an increased risk for cardiovascular disease and myeloid malignancies 150,151 .”
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“Even though the immune-suppressive effect of corticosteroids has since been established 163 , most studies of steroid function in antitumour treatment remain focused on direct cytotoxic effects.”
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · cited 1×
“IMiDs also have direct cytotoxic effects through ubiquitylation and subsequent targeting for degradation of transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos) in tumour cells 172 .”
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“55), an important driver of MM pathobiology that promotes proliferation and survival of primary MM cells 105 and myeloma cell lines 106 .”
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“Transfer of transduced cells in recipient mice induces AML 227 .”
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115
Self-citationCompetence and competition: the challenge of becoming a long-lived plasma cell
Radbruch, A., Muehlinghaus, G., Luger, E. O., Inamine, A., Smith, K. G. C., Dörner, T., & Hiepe, F. (2006) · Nature Reviews Immunology · doi:10.1038/nri1886 · Cited by 1,030
Haematopoietic stem cell activity and interactions with the niche
Pinho, S., & Frenette, P. S. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0103-9 · Cited by 984
Distinct fibroblast subsets drive inflammation and damage in arthritis
Croft, A. P., Campos, J., Jansen, K., Turner, J. D., Marshall, J., Attar, M., Savary, L., Wehmeyer, C., Naylor, A. J., Kemble, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1263-7 · Cited by 976 · cited 1×
“Such stromal cell contribution to chronic inflammation is evident in studies of autoimmune diseases, in which activated stromal cells are driving chronicity and are sufficient to reactivate inflammation upon transfer into naive mice 188 .”
A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia
Baryawno, N., Przybylski, D., Kowalczyk, M. S., Kfoury, Y., Severe, N., Gustafsson, K., Kokkaliaris, K. D., Mercier, F., Tabaka, M., Hofree, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.040 · Cited by 884
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Cellular Niches Controlling B Lymphocyte Behavior within Bone Marrow during Development
Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B.-I., & Nagasawa, T. (2004) · Immunity · doi:10.1016/j.immuni.2004.05.001 · Cited by 796
Hematopoietic stem cell niche maintenance during homeostasis and regeneration
Mendelson, A., & Frenette, P. S. (2014) · Nature Medicine · doi:10.1038/nm.3647 · Cited by 792
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
The spectrum of inflammatory responses
Medzhitov, R. (2021) · Science · doi:10.1126/science.abi5200 · Cited by 718
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709974 · Cited by 647
Schepers, K., Pietras, E. M., Reynaud, D., Flach, J., Binnewies, M., Garg, T., Wagers, A. J., Hsiao, E. C., & Passegué, E. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.009 · Cited by 614
Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., & Pardanani, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9490 · Cited by 608
The ageing haematopoietic stem cell compartment
Geiger, H., de Haan, G., & Florian, M. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3433 · Cited by 604 · cited 1×
“A main feature of inflammageing is the overall increase in numbers of circulating myeloid cells and BM-dwelling myeloid progenitors 141,142 .”
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R. A., et al. (2010) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 577
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C.-W., Ramakrishnan, A., Li, Y., Chung, Y. R., Micol, J.-B., Murphy, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.006 · Cited by 575
In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche
Fujisaki, J., Wu, J., Carlson, A. L., Silberstein, L., Putheti, P., Larocca, R., Gao, W., Saito, T. I., Celso, C. L., Tsuyuzaki, H., et al. (2011) · Nature · doi:10.1038/nature10160 · Cited by 567
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency
Walkley, C. R., Olsen, G. H., Dworkin, S., Fabb, S. A., Swann, J., McArthur, G. A., Westmoreland, S. V., Chambon, P., Scadden, D. T., & Purton, L. E. (2007) · Cell · doi:10.1016/j.cell.2007.05.014 · Cited by 536
Eosinophils are required for the maintenance of plasma cells in the bone marrow
Chu, V. T., Fröhlich, A., Steinhauser, G., Scheel, T., Roch, T., Fillatreau, S., Lee, J. J., Löhning, M., & Berek, C. (2011) · Nature Immunology · doi:10.1038/ni.1981 · Cited by 519
Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals
Cassese, G., Arce, S., Hauser, A. E., Lehnert, K., Moewes, B., Mostarac, M., Muehlinghaus, G., Szyska, M., Radbruch, A., & Manz, R. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1684 · Cited by 487 · cited 1×
“…MM and AML share transcription of activation-related genes, a major difference is the fact that the expression of CXCL12 , LEPR and KITLG is maintained in MM-associated stromal cells but not in AML-associated stromal cells 42,57 , with CXCL12 being imperative for BM retention of MM cells 29,58 .”
Bone marrow niches in haematological malignancies
Méndez-Ferrer, S., Bonnet, D., Steensma, D. P., Hasserjian, R. P., Ghobrial, I. M., Gribben, J. G., Andreeff, M., & Krause, D. S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0245-2 · Cited by 484
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Haas, S., Hansson, J., Klimmeck, D., Loeffler, D., Velten, L., Uckelmann, H., Wurzer, S., Prendergast, Á. M., Schnell, A., Hexel, K., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.07.007 · Cited by 471 · cited 1×
“In myelofibrosis, a disease characterized by progressive deposition of reticulin fibres in the bone marrow, inflammageing-related changes induce megakaryocyte-biased haematopoiesis 211,212 .”
Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000349 · Cited by 458
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014) · Nature · doi:10.1038/nature13383 · Cited by 444
Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Immune ageing at single-cell resolution
Mogilenko, D. A., Shchukina, I., & Artyomov, M. N. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00646-4 · Cited by 381
Obeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380
Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374 · cited 5×
“…+ monocytes in the BM of individuals with MGUS and smoul-dering MM compared with patients without cancer 7,146,147 , although there have been occasional reports of an overall decrease in other myeloid populations 7 , which is in contrast to the inflammageing-related increases of these cell types.”
InfluentialOgawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 367
Tai, Y.-T., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 350
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730556 · Cited by 348
Hashizume, M., Hayakawa, N., & Mihara, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken363 · Cited by 347
Inflammation-associated S100 proteins: new mechanisms that regulate function
Goyette, J., & Geczy, C. L. (2011) · Amino Acids · doi:10.1007/s00726-010-0528-0 · Cited by 345
Grover, A., Sanjuan-Pla, A., Thongjuea, S., Carrelha, J., Giustacchini, A., Gambardella, A., Macaulay, I., Mancini, E., Luis, T. C., Mead, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11075 · Cited by 345
Zambetti, N. A., Ping, Z., Chen, S., Kenswil, K. J. G., Mylona, M. A., Sanders, M. A., Hoogenboezem, R. M., Bindels, E. M. J., Adisty, M. N., Van Strien, P. M. H., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.021 · Cited by 342
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335 · cited 1×
“Pro-liferative HSCs are associated with niches containing megakaryocytes and macrophages, leptin receptor-expressing MSCs and sinusoidal endothelial cells 18 , which secrete proteins such as CXCL12, stem cell factor (SCF), IL-6, granulocyte colony-stimulating factor (G-CSF) and IL-1β 19–21 .”
Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling
Hormaechea-Agulla, D., Matatall, K. A., Le, D. T., Kain, B., Long, X., Kus, P., Jaksik, R., Challen, G. A., Kimmel, M., & King, K. Y. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.03.002 · Cited by 329
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328 · cited 1×
“…cells in MM have increased production of inflammation-related signals, including IL-3, G-CSF and macrophage colony-stimulating factor (M-CSF) 59 , as well as increased transcription of the chemokines CXCL2 , CXCL3 , CXCL5 , CXCL8 , CCL2 and CCL3 , and complement component 3 ( C3 ) 57,60,61 .”
Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML
Duarte, D., Hawkins, E. D., Akinduro, O., Ang, H., De Filippo, K., Kong, I. Y., Haltalli, M., Ruivo, N., Straszkowski, L., Vervoort, S. J., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.11.006 · Cited by 324
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Abdel-Wahab, O., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y. R., Kuscu, C., Hricik, T., Ndiaye-Lobry, D., LaFave, L. M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131141 · Cited by 322
Bharti, A. C., Shishodia, S., Reuben, J. M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M., & Aggarwal, B. B. (2004) · Blood · doi:10.1182/blood-2003-06-2151 · Cited by 318
Nishio, M., Endo, T., Tsukada, N., Ohata, J., Kitada, S., Reed, J. C., Zvaifler, N. J., & Kipps, T. J. (2005) · Blood · doi:10.1182/blood-2004-03-0889 · Cited by 317
Zheng, Y., Cai, Z., Wang, S., Zhang, X., Qian, J., Hong, S., Li, H., Wang, M., Yang, J., & Yi, Q. (2009) · Blood · doi:10.1182/blood-2009-05-220285 · Cited by 307
Fayad, L., Keating, M. J., Reuben, J. M., O'Brien, S., Lee, B.-N., Lerner, S., & Kurzrock, R. (2001) · Blood · doi:10.1182/blood.v97.1.256 · Cited by 290
Marnell, C. S., Bick, A., & Natarajan, P. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.07.004 · Cited by 289
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Demchenko, Y. N., Glebov, O. K., Zingone, A., Keats, J. J., Bergsagel, P. L., & Kuehl, W. M. (2010) · Blood · doi:10.1182/blood-2009-09-243535 · Cited by 288
Yan, M., Kanbe, E., Peterson, L. F., Boyapati, A., Miao, Y., Wang, Y., Chen, I.-M., Chen, Z., Rowley, J. D., Willman, C. L., et al. (2006) · Nature Medicine · doi:10.1038/nm1443 · Cited by 279 · cited 1×
“Mouse HSCs are transduced with the AML1-ETO fusion oncoprotein, associated with translocation t(8;21) in patients 225 , and transplanted into lethally irradiated recipient mice that will rapidly develop a severe leukaemia resembling human AML 226 .”
Mouse models of human AML accurately predict chemotherapy response
Zuber, J., Radtke, I., Pardee, T. S., Zhao, Z., Rappaport, A. R., Luo, W., McCurrach, M. E., Yang, M.-M., Dolan, M. E., Kogan, S. C., et al. (2009) · Genes & Development · doi:10.1101/gad.1771409 · Cited by 279
Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity
Kennel, K. B., Bozlar, M., De Valk, A. F., & Greten, F. R. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1031 · Cited by 279
Zhou, Y., Bian, S., Zhou, X., Cui, Y., Wang, W., Wen, L., Guo, L., Fu, W., & Tang, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.015 · Cited by 278
Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270 · cited 3×
“For example, the progression from myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML) is associated with inflammatory signalling in the BM 3,4 , and in a mouse model of AML, interleukin-1β (IL-1β) is a major driver of disease progression 5 .”
Autocrine secretion of GM-CSF in acute myeloblastic leukemia
Young, D., & Griffin, J. (1986) · Blood · doi:10.1182/blood.v68.5.1178.1178 · Cited by 269
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment
Dong, L., Yu, W.-M., Zheng, H., Loh, M. L., Bunting, S. T., Pauly, M., Huang, G., Zhou, M., Broxmeyer, H. E., Scadden, D. T., et al. (2016) · Nature · doi:10.1038/nature20131 · Cited by 262
Gunn, W. G., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., & Gregory, C. A. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0220 · Cited by 261
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 255
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
de Jong, M. M. E., Kellermayer, Z., Papazian, N., Tahri, S., Hofste op Bruinink, D., Hoogenboezem, R., Sanders, M. A., van de Woestijne, P. C., Bos, P. K., Khandanpour, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00931-3 · Cited by 250 · cited 19×
“Stromal cells of the MM cell niche have an activated phenotype, associated with TNF-induced or IL-1β-induced NF-κB signalling, and account for up to 40% of stromal cells in BM aspirates 57 , suggesting that the frequency of stromal cells transcribing plasma cell survival factors is strongly increased.”
InfluentialSelf-citationDiagnosis and Treatment of Myelodysplastic Syndromes: A Review
Sekeres, M. A., & Taylor, J. (2022) · JAMA · doi:10.1001/jama.2022.14578 · Cited by 250
Two to Tango: Dialog between Immunity and Stem Cells in Health and Disease
Naik, S., Larsen, S. B., Cowley, C. J., & Fuchs, E. (2018) · Cell · doi:10.1016/j.cell.2018.08.071 · Cited by 248
Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., Gordon-Mitchell, S., Von Ahrens, D., Pradhan, K., Steeples, V., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0314-5 · Cited by 247
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 246
Geyh, S., Öz, S., Cadeddu, R.-P., Fröbel, J., Brückner, B., Kündgen, A., Fenk, R., Bruns, I., Zilkens, C., Hermsen, D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.193 · Cited by 238
Organization of immunological memory by bone marrow stroma
Tokoyoda, K., Hauser, A. E., Nakayama, T., & Radbruch, A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2727 · Cited by 236
Ong, S.-M., Hadadi, E., Dang, T.-M., Yeap, W.-H., Tan, C. T.-Y., Ng, T.-P., Larbi, A., & Wong, S.-C. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0327-1 · Cited by 233
Görgün, G., Calabrese, E., Soydan, E., Hideshima, T., Perrone, G., Bandi, M., Cirstea, D., Santo, L., Hu, Y., Tai, Y.-T., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279893 · Cited by 230
Lin, Y.-W., Slape, C., Zhang, Z., & Aplan, P. D. (2005) · Blood · doi:10.1182/blood-2004-12-4794 · Cited by 230
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity
Kagoya, Y., Yoshimi, A., Kataoka, K., Nakagawa, M., Kumano, K., Arai, S., Kobayashi, H., Saito, T., Iwakura, Y., & Kurokawa, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68101 · Cited by 227
Chronic immune response dysregulation in MDS pathogenesis
Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226 · cited 1×
“For example, the progression from myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML) is associated with inflammatory signalling in the BM 3,4 , and in a mouse model of AML, interleukin-1β (IL-1β) is a major driver of disease progression 5 .”
Sanchez-Correa, B., Bergua, J. M., Campos, C., Gayoso, I., Arcos, M. J., Bañas, H., Morgado, S., Casado, J. G., Solana, R., & Tarazona, R. (2013) · Cytokine · doi:10.1016/j.cyto.2012.12.023 · Cited by 208
Fuster, J. J., Zuriaga, M. A., Zorita, V., MacLauchlan, S., Polackal, M. N., Viana-Huete, V., Ferrer-Pérez, A., Matesanz, N., Herrero-Cervera, A., Sano, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108326 · Cited by 204 · cited 1×
“72) (increasing TRAF6 and IRAK1 expression), spliceosome mutations such as U2AF1 mutations 73 , or somatic TET2 mutations 74 .”
Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199
Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis
Avagyan, S., Henninger, J. E., Mannherz, W. P., Mistry, M., Yoon, J., Yang, S., Weber, M. C., Moore, J. L., & Zon, L. I. (2021) · Science · doi:10.1126/science.aba9304 · Cited by 192
Ferrajoli, A., Keating, M. J., Manshouri, T., Giles, F. J., Dey, A., Estrov, Z., Koller, C. A., Kurzrock, R., Thomas, D. A., Faderl, S., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1215.h81602001215_1215_1219 · Cited by 191
Arnulf, B., Lecourt, S., Soulier, J., Ternaux, B., Lacassagne, M.-N., Crinquette, A., Dessoly, J., Sciaini, A.-K., Benbunan, M., Chomienne, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404466 · Cited by 190 · cited 2×
“…cells in MM have increased production of inflammation-related signals, including IL-3, G-CSF and macrophage colony-stimulating factor (M-CSF) 59 , as well as increased transcription of the chemokines CXCL2 , CXCL3 , CXCL5 , CXCL8 , CCL2 and CCL3 , and complement component 3 ( C3 ) 57,60,61 .”
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189 · cited 1×
“Mirroring observations in MDS and AML, the prevailing hypothesis in CHIP is that inflammatory signals are derived from the clonal cells and that these signals repress normal haematopoiesis, whereas mutated cells are relatively resistant to these insults 42,52,154–156 .”
Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis
Leimkühler, N. B., Gleitz, H. F. E., Ronghui, L., Snoeren, I. A. M., Fuchs, S. N. R., Nagai, J. S., Banjanin, B., Lam, K. H., Vogl, T., Kuppe, C., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2020.11.004 · Cited by 176
Jourdan, M., Cren, M., Robert, N., Bolloré, K., Fest, T., Duperray, C., Guilloton, F., Hose, D., Tarte, K., & Klein, B. (2014) · Leukemia · doi:10.1038/leu.2014.61 · Cited by 175
Blau, O., Baldus, C. D., Hofmann, W.-K., Thiel, G., Nolte, F., Burmeister, T., Türkmen, S., Benlasfer, O., Schümann, E., Sindram, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343467 · Cited by 173
Bailur, J. K., McCachren, S. S., Doxie, D. B., Shrestha, M., Pendleton, K., Nooka, A. K., Neparidze, N., Parker, T. L., Bar, N., Kaufman, J. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127807 · Cited by 171
Dissecting racial disparities in multiple myeloma
Marinac, C. R., Ghobrial, I. M., Birmann, B. M., Soiffer, J. L., & Rebbeck, T. R. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0284-7 · Cited by 169
Mouhieddine, T. H., Sperling, A. S., Redd, R., Park, J., Leventhal, M., Gibson, C. J., Manier, S., Nassar, A. H., Capelletti, M., Huynh, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16805-5 · Cited by 167
Rodriguez-Meira, A., Norfo, R., Wen, S., Chédeville, A. L., Rahman, H., O’Sullivan, J., Wang, G., Louka, E., Kretzschmar, W. W., Paterson, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01480-1 · Cited by 158 · cited 1×
“157).”
Al-Matary, Y. S., Botezatu, L., Opalka, B., Hones, J. M., Lams, R. F., Thivakaran, A., Schutte, J., Koster, R., Lennartz, K., Schroeder, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143180 · Cited by 155
Garayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148 · cited 1×
“MM show genomic abnormalities distinct from those typically found in MM cells 61,65 .”
Perez, C., Botta, C., Zabaleta, A., Puig, N., Cedena, M.-T., Goicoechea, I., Alameda, D., San José-Eneriz, E., Merino, J., Rodríguez-Otero, P., et al. (2020) · Blood · doi:10.1182/blood.2019004537 · Cited by 146
Tirier, S. M., Mallm, J.-P., Steiger, S., Poos, A. M., Awwad, M. H. S., Giesen, N., Casiraghi, N., Susak, H., Bauer, K., Baumann, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26951-z · Cited by 145
Dybedal, I., Bryder, D., Fossum, A., Rusten, L. S., & Jacobsen, S. E. W. (2001) · Blood · doi:10.1182/blood.v98.6.1782 · Cited by 144
Hanna, B. S., McClanahan, F., Yazdanparast, H., Zaborsky, N., Kalter, V., Rößner, P. M., Benner, A., Dürr, C., Egle, A., Gribben, J. G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.305 · Cited by 144
S100A9 induces differentiation of acute myeloid leukemia cells through TLR4
Laouedj, M., Tardif, M. R., Gil, L., Raquil, M.-A., Lachhab, A., Pelletier, M., Tessier, P. A., & Barabé, F. (2017) · Blood · doi:10.1182/blood-2016-09-738005 · Cited by 140
Maratheftis, C. I., Andreakos, E., Moutsopoulos, H. M., & Voulgarelis, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2108 · Cited by 139
Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene
Dobson, C., Warren, A. J., Pannell, R., Forster, A. M., & Rabbitts, T. H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.843 · Cited by 137
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
Lv, M., Wang, K., & Huang, X. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0797-3 · Cited by 136
Fucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731737 · Cited by 135 · cited 2×
“Various other DAMPs, including calreticulin, HMGB1 and HSP70, are also increased in the serum of patients with AML compared with controls 82 and probably have a role in further amplifying innate inflammatory signalling in the tumour and its microenvironment.”
Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova‐Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23868 · Cited by 133
Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells
Zehentmeier, S., Roth, K., Cseresnyes, Z., Sercan, Ö., Horn, K., Niesner, R. A., Chang, H., Radbruch, A., & Hauser, A. E. (2014) · European Journal of Immunology · doi:10.1002/eji.201344313 · Cited by 131
Plasma cells are obligate effectors of enhanced myelopoiesis in aging bone marrow
Pioli, P. D., Casero, D., Montecino-Rodriguez, E., Morrison, S. L., & Dorshkind, K. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.006 · Cited by 131
Cryptic glucocorticoid receptor-binding sites pervade genomic NF-κB response elements
Hudson, W. H., Vera, I. M. S. D., Nwachukwu, J. C., Weikum, E. R., Herbst, A. G., Yang, Q., Bain, D. L., Nettles, K. W., Kojetin, D. J., & Ortlund, E. A. (2018) · Nature Communications · doi:10.1038/s41467-018-03780-1 · Cited by 130
Shi, L., Qin, X., Wang, H., Xia, Y., Li, Y., Chen, X., Shang, L., Tai, Y., Feng, X., Acharya, P. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13320 · Cited by 124
Mupo, A., Seiler, M., Sathiaseelan, V, Pance, A., Yang, Y., Agrawal, A. A., Iorio, F., Bautista, R., Pacharne, S., Tzelepis, K., et al. (2017) · Leukemia · doi:10.1038/leu.2016.251 · Cited by 123
Kim, J., Denu, R. A., Dollar, B. A., Escalante, L. E., Kuether, J. P., Callander, N. S., Asimakopoulos, F., & Hematti, P. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09154.x · Cited by 122
Paiva, B., Pérez‐Andrés, M., Vídriales, M., Almeida, J., Heras, N. D. L., Mateos, M., López‐Corral, L., Gutierrez, N. C., Blanco, J. F., Oriol, A., et al. (2011) · Leukemia · doi:10.1038/leu.2010.320 · Cited by 119
Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients
Wallace, S. R., Oken, M. M., Lunetta, K. L., Panoskaltsis-Mortari, A., & Masellis, A. M. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1219::aid-cncr1122>3.0.co;2-1 · Cited by 116
c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling
Peruzzi, B., Cappariello, A., Fattore, A. D., Rucci, N., Benedetti, F. D., & Teti, A. M. (2012) · Nature Communications · doi:10.1038/ncomms1651 · Cited by 116
Litmanovich, A., Khazim, K., & Cohen, I. (2018) · Oncology and Therapy · doi:10.1007/s40487-018-0089-z · Cited by 116
Li, K., Du, Y., Cai, Y., Liu, W., Lv, Y., Huang, B., Zhang, L., Wang, Z., Liu, P., Sun, Q., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01789-6 · Cited by 116
Inter‐chromosomal recombination of Mll and Af9 genes mediated by cre‐ loxP in mouse development
Collins, E. C., Pannell, R., Simpson, E. M., Forster, A., & Rabbitts, T. H. (2000) · EMBO reports · doi:10.1093/embo-reports/kvd021 · Cited by 112
Gleitz, H. F. E., Dugourd, A. J. F., Leimkühler, N. B., Snoeren, I., Fuchs, S. N. R., Menzel, S., Ziegler, S. M., Kröger, N. M., Triviai, I., Büsche, G., et al. (2020) · Blood · doi:10.1182/blood.2019004095 · Cited by 112
Balderman, S., Li, A. J., Hoffman, C. M., Frisch, B. J., Goodman, A. N., LaMere, M. W., Georger, M. A., Evans, A. G., Liesveld, J. L., Becker, M. W., et al. (2015) · Blood · doi:10.1182/blood-2015-06-653113 · Cited by 108
Matthes, T., Dunand-Sauthier, I., Santiago-Raber, M.-L., Krause, K.-H., Donze, O., Passweg, J., McKee, T., & Huard, B. (2011) · Blood · doi:10.1182/blood-2011-01-332940 · Cited by 107
Xu, S., Menu, E., Becker, A. D., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012) · Stem Cells · doi:10.1002/stem.787 · Cited by 103
Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.
Jourdan, M., Tarte, K., Legouffe, É., Brochier, J., Rossi, J., & Klein, B. (1999) · PubMed · Cited by 102
Tumor-associated macrophages as a prognostic parameter in multiple myeloma
Suyanı, E., Sucak, G. T., Akyürek, N., Şahin, S., Baysal, N. A., Yağcı, M., & Haznedar, R. (2013) · Annals of Hematology · doi:10.1007/s00277-012-1652-6 · Cited by 101
Yang, X., Feng, W., Wang, R., Yang, F., Wang, L., Chen, S., Ru, Y., Cheng, T., & Zheng, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1412910 · Cited by 101
Cheng, P., Eksioglu, E. A., Chen, X., Kandell, W., Le Trinh, T., Cen, L., Qi, J., Sallman, D. A., Zhang, Y., Tu, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0397-9 · Cited by 101
Cosgrove, J., Hustin, L., de Boer, R. J., & Perié, L. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.006 · Cited by 101
Giallongo, C., Tibullo, D., Parrinello, N. L., La Cava, P., Di Rosa, M., Bramanti, V., Di Raimondo, C., Conticello, C., Chiarenza, A., Palumbo, G. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7969 · Cited by 100
Hofbauer, D., Mougiakakos, D., Broggini, L., Zaiss, M., Büttner-Herold, M., Bach, C., Spriewald, B., Neumann, F., Bisht, S., Nolting, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.002 · Cited by 100
Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 100
SanMiguel, J. M., Eudy, E., Loberg, M. A., Young, K. A., Mistry, J. J., Mujica, K. D., Schwartz, L. S., Stearns, T. M., Challen, G. A., & Trowbridge, J. J. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0086 · Cited by 97
Brauneck, F., Fischer, B., Witt, M., Muschhammer, J., Oelrich, J., Avelar, P., Tsoka, S., Bullinger, L., Seubert, E., Smit, D. J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004794 · Cited by 95
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML
Volk, A., Li, J., Xin, J., You, D., Zhang, J., Liu, X., Xiao, Y., Breslin, P., Li, Z., Wei, W., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130990 · Cited by 94
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Yeaton, A., Cayanan, G., Loghavi, S., Dolgalev, I., Leddin, E. M., Loo, C. E., Torabifard, H., Nicolet, D., Wang, J., Corrigan, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1146 · Cited by 94
Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production
Costes, V., Portier, M., Lu, Z., Rossi, J., Bataille, R., & Klein, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01101.x · Cited by 87
Pronk, E., & Raaijmakers, M. H. G. P. (2019) · Blood · doi:10.1182/blood-2018-10-844639 · Cited by 86
Self-citationHenry, J. Y., Labarthe, M., Meyer, B., Dasgupta, P., Dalgleish, A. G., & Galustian, C. (2013) · Immunology · doi:10.1111/imm.12087 · Cited by 85
Brück, O. E., Dufva, O., Hohtari, H. R., Blom, S., Turkki, R., Ilander, M. M., Kovanen, P. E., Pallaud, C., Ramos, P. M., Lähteenmäki, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000792 · Cited by 80
Chen, S., Zambetti, N. A., Bindels, E. M. J., Kenswill, K., Mylona, A. M., Adisty, N. M., Hoogenboezem, R. M., Sanders, M. A., Cremers, E. M. P., Westers, T. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.91 · Cited by 79 · cited 3×
“32).”
Self-citationCorradi, G., Bassani, B., Simonetti, G., Sangaletti, S., Vadakekolathu, J. N., Fontana, M. C., Pazzaglia, M., Gulino, A., Tripodo, C., Cristiano, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3594 · Cited by 79
Hofgaard, P. O., Jodal, H. C., Bommert, K., Huard, B., Caers, J., Carlsen, H., Schwarzer, R., Schünemann, N., Jundt, F., Lindeberg, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051892 · Cited by 76
Wang, H., Hu, W.-M., Xia, Z.-J., Liang, Y., Lu, Y., Lin, S.-X., & Tang, H. (2019) · Journal of Cancer · doi:10.7150/jca.30102 · Cited by 76
Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients
Nicolas‐Virelizier, E., Ramus, C., Berthier, S., Arlotto, M., Bouamrani, A., Lefebvre, C., Morel, F., Garin, J., Ifrah, N., Berger, F. R., et al. (2010) · Leukemia · doi:10.1038/leu.2010.251 · Cited by 75
IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia
Zhang, T. Y., Dutta, R., Benard, B., Zhao, F., Yin, R., & Majeti, R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5104 · Cited by 75
Mourcin, F., Verdière, L., Roulois, D., Amin, R., Lamaison, C., Sibut, V., Thamphya, B., Pangault, C., Monvoisin, C., Huet, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.019 · Cited by 75
Schinke, C., Poos, A. M., Bauer, M., John, L., Johnson, S., Deshpande, S., Carrillo, L. F., Alapat, D. V., Rasche, L., Thanendrarajan, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007217 · Cited by 75
Mei, Y., Ren, K., Liu, Y., Ma, A., Xia, Z., Han, X., Li, E., Tariq, H., Bao, H., Xie, X., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152673 · Cited by 74
Shi, L., Zhao, Y., Fei, C., Guo, J., Jia, Y., Wu, D., Wu, L., & Chang, C. (2019) · Aging · doi:10.18632/aging.102409 · Cited by 73
Grégoire, M., Guilloton, F., Pangault, C., Mourcin, F., Sok, P., Latour, M., Amé-Thomas, P., Flecher, E., Fest, T., & Tarte, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4106 · Cited by 72
Tsimberidou, A. M., Waddelow, T. A., Kantarjian, H. M., Albitar, M. X., & Giles, F. J. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00082-6 · Cited by 69
Tumour‐associated macrophage‐mediated survival of myeloma cells through STAT3 activation
De Beule, N., De Veirman, K., Maes, K., De Bruyne, E., Menu, E., Breckpot, K., De Raeve, H., Van Rampelbergh, R., Van Ginderachter, J. A., Schots, R., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4860 · Cited by 69
The evolving view of the hematopoietic stem cell niche
Beerman, I., Luis, T. C., Singbrant, S., Lo Celso, C., & Méndez-Ferrer, S. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.01.008 · Cited by 69
Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia
Tobler, A., Moser, B., Dewald, B., Geiser, T., Studer, H., Baggiolini, M., & Fey, M. (1993) · Blood · doi:10.1182/blood.v82.8.2517.2517 · Cited by 68
Everson, M., Brown, C., & Lilly, M. (1989) · Blood · doi:10.1182/blood.v74.5.1472.1472 · Cited by 68
Warzocha, K., Bienvenu, J., Ribeiro, P., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.391 · Cited by 67
Balandrán, J. C., Purizaca, J., Enciso, J., Dozal, D., Sandoval-Cabrera, A., Jiménez‐Hernández, E., Alemán‐Lazarini, L., Pérez‐Koldenkova, V., del Prado, H. Q.-N., Ríos, J. R. D. L., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00666 · Cited by 67
EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis
Malara, A., Gruppi, C., Abbonante, V., Cattaneo, D., Marco, L. D., Massa, M., Iurlo, A., Gianelli, U., Balduini, C. L., Tira, M. E., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181074 · Cited by 65
Hou, D., Wang, B., You, R., Wang, X., Liu, J., Zhan, W., Chen, P., Qin, T., Zhang, X., & Huang, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3191 · Cited by 64
Bernitz, J. M., Daniel, M. G., Fstkchyan, Y. S., & Moore, K. (2017) · Blood · doi:10.1182/blood-2016-11-752923 · Cited by 61
CXCR4–CXCL12 interaction is important for plasma cell homing and survival in NZB/W mice
Cheng, Q., Khodadadi, L., Taddeo, A., Klotsche, J., F. Hoyer, B., Radbruch, A., & Hiepe, F. (2018) · European Journal of Immunology · doi:10.1002/eji.201747023 · Cited by 60
Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
Villatoro, A., Cuminetti, V., Bernal, A., Torroja, C., Cossío, I., Benguría, A., Ferré, M., Konieczny, J., Vázquez, E., Rubio, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35700-9 · Cited by 59
IL-6 and MYC collaborate in plasma cell tumor formation in mice
Rutsch, S., Neppalli, V. T., Shin, D.-M., DuBois, W., Morse, H. C., Goldschmidt, H., & Janz, S. (2010) · Blood · doi:10.1182/blood-2009-08-237941 · Cited by 58
Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia
Hanna, B. S., Öztürk, S., & Seiffert, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.014 · Cited by 57
Søegaard, S. H., Rostgaard, K., Skogstrand, K., Wiemels, J. L., Schmiegelow, K., & Hjalgrim, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0831 · Cited by 57
The inflammatory cytokine profile of myelodysplastic syndromes: A meta-analysis
Shi, X., Zheng, Y., Xu, L., Cao, C., Dong, B., & Chen, X. (2019) · Medicine · doi:10.1097/md.0000000000015844 · Cited by 57
NLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia via IL-1β Pathway
Zhong, C., Wang, R., Hua, M., Zhang, C., Han, F., Xu, M., Yang, X., Li, G., Hu, X., Sun, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661939 · Cited by 56
Orelio, C., Haak, E., Peeters, M., & Dzierzak, E. (2008) · Blood · doi:10.1182/blood-2007-12-123836 · Cited by 52
The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms
Balandrán, J. C., Lasry, A., & Aifantis, I. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0176 · Cited by 52
Ping, Z., Chen, S., Hermans, S. J. F., Kenswil, K. J. G., Feyen, J., van Dijk, C., Bindels, E. M., Mylona, A., Adisty, N., Hoogenboezem, R. M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0267-x · Cited by 51
Self-citationRibezzo, F., Snoeren, I. A. M., Ziegler, S., Stoelben, J., Olofsen, P. A., Henic, A., Ferreira, M. V., Chen, S., Stalmann, U. S. A., Buesche, G., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0350-3 · Cited by 51 · cited 1×
“These stromal alterations are induced directly by inflammatory signals from mutated myeloid cells 38 and culminate in the decreased transcription of key HSPC niche factors, including KITLG (encoding SCF) and CXCL12 (refs.”
Self-citationChen, B.-Y., Song, J., Hu, C.-L., Chen, S.-B., Zhang, Q., Xu, C.-H., Wu, J.-C., Hou, D., Sun, M., Zhang, Y.-L., et al. (2020) · Blood · doi:10.1182/blood.2019001963 · Cited by 50
Dosani, T., Covut, F., Beck, R. C., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.60 · Cited by 48
de Boer, B., Sheveleva, S., Apelt, K., Vellenga, E., Mulder, A. B., Huls, G. A., & Schuringa, J. J. (2020) · Haematologica · doi:10.3324/haematol.2020.254987 · Cited by 48
Gu, J., Huang, X., Zhang, Y., Bao, C., Zhou, Z., & Jin, J. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155358 · Cited by 47
Scott, B. L., Ramakrishnan, A., Fosdal, M., Storer, B. E., Becker, P. S., Petersdorf, S., & Deeg, H. J. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08145.x · Cited by 46
Colombo, M., Galletti, S., Bulfamante, G., Falleni, M., Tosi, D., Todoerti, K., Lazzari, E., Crews, L. A., Jamieson, C. H. M., Ravaioli, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10820 · Cited by 45
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin
Yu, S., Ren, X., & Li, L. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00296-9 · Cited by 45
Maia, C., Puig, N., Cedena, M., Goicoechea, I., Valdés‐Mas, R., Vázquez, I., Chillón, C., Aguirre‐Ruiz, P., Sarvide, S., Gracia-Aznárez, F. J., et al. (2020) · Blood · doi:10.1182/blood.2019003382 · Cited by 44
The Bone Marrow Endosteal Niche: How Far from the Surface?
Cordeiro-Spinetti, E., Taichman, R. S., & Balduíno, A. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24952 · Cited by 43
Gätjen, M., Brand, F., Grau, M., Gerlach, K., Kettritz, R., Westermann, J., Anagnostopoulos, I., Lenz, P., Lenz, G., Höpken, U. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3486 · Cited by 43
Therapeutic targeting of the inflammasome in myeloid malignancies
Chakraborty, S., Shapiro, L. C., de Oliveira, S., Rivera-Peña, B., Verma, A. K., & Shastri, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00547-8 · Cited by 42
Chen, L., Pronk, E., van Dijk, C., Bian, Y., Feyen, J., van Tienhoven, T. V. D., Yildirim, M., Pisterzi, P., de Jong, M. M. E., Bastidas, A., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0043 · Cited by 42
Self-citationKarjalainen, R., Liu, M., Kumar, A., He, L., Malani, D., Parsons, A., Kontro, M., Kallioniemi, O., Porkka, K., & Heckman, C. A. (2019) · Leukemia · doi:10.1038/s41375-019-0504-y · Cited by 41
Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells
Wang, X., Zhang, Z.-Q., & Cheng, Y. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.05.006 · Cited by 40
Furukawa, M., Ohkawara, H., Ogawa, K., Ikeda, K., Ueda, K., Shichishima-Nakamura, A., Ito, E., Imai, J.-I., Yanagisawa, Y., Honma, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.733030 · Cited by 40
Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα
Akhmetzyanova, I., Aaron, T., Galbo, P., Tikhonova, A., Dolgalev, I., Tanaka, M., Aifantis, I., Zheng, D., Zang, X., & Fooksman, D. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005327 · Cited by 39
STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia
Fleur-Lominy, S. S., Maus, M., Vaeth, M., Lange, I., Zee, I., Suh, D. Y., Liu, C.-J., Wu, X., Tikhonova, A. N., Aifantis, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.030 · Cited by 38
Wong, D. M., Winter, O., Hartig, C., Siebels, S., Szyska, M., Tiburzy, B., Meng, L., Kulkarni, U., Fähnrich, A., Bommert, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109018 · Cited by 37
Induction of Malignant Plasma Cell Proliferation by Eosinophils
Wong, T. W., Kita, H., Hanson, C. A., Walters, D. K., Arendt, B. K., & Jelinek, D. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070554 · Cited by 37
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
Beyar‐Katz, O., Magidey, K., Benaim, A. R., Barak, N., Avivi, I. M., Cohen, Y. C., Timaner, M., Avraham, S., Hayun, M., Lavi, N., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0487 · Cited by 36
Bao, C., Gu, J., Huang, X., You, L., Zhou, Z., & Jin, J. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156289 · Cited by 36
Tsubaki, M., Komai, M., Itoh, T., Imano, M., Sakamoto, K., Shimaoka, H., Ogawa, N., Mashimo, K., Fujiwara, D., Takeda, T., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.010 · Cited by 35
Cimino, G. G., Amadori, S., Cava, M. C., et al. (1991) · PubMed · Cited by 35
Chitre, S., Stölzel, F., Cuthill, K., Streetly, M., Graham, C., Dill, C., Mohamedali, A. M., Smith, A., Schetelig, J., Altmann, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0208-8 · Cited by 35
Cited by
The role of the haematopoietic stem cell niche in development and ageing
Cain, T. L., Derecka, M., & McKinney‐Freeman, S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00770-8 · Cited by 85
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 36
“The ECM comprises fibrous proteins, proteoglycans and glycosaminoglycans, whereas the soluble factors include a broader range of molecules such as chemokines, cytokines, growth factors, exosomes, nutrients and oxygen.”
Lutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp6667 · Cited by 25
Blanquart, E., Ekren, R., Rigaud, B., Joubert, M.-V., Baylot, V., Daunes, H., Cuisinier, M., Villard, M., Carrié, N., Mazzotti, C., et al. (2024) · Blood · doi:10.1182/blood.2023023529 · Cited by 29
Lim, J. J., Vining, K. H., Mooney, D. J., & Blencowe, B. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404146121 · Cited by 16
Metadata
- Authors
- de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T.
- Affiliations
- Erasmus MC Cancer Institute (NL)
- Corresponding author
- Cupedo, Tom
- Venue
- Nature reviews. Immunology
- Published
- 2024-03-15
- Volume
- 24
- Issue
- 8
- Pages
- 543-558
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W4392864858
- Semantic Scholar
- 8eec83c2a7c101d4a5f7a8e938c4a09b89c96da5
- Cited by
- 54
- References
- 238
- Citations by year
- 2026: 27 · 2025: 20 · 2024: 7
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Funders
- KWF Kankerbestrijding (11092)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- bone marrow inflammation, tumour-associated inflammation, tumor microenvironment, hematologic malignancies, acute myeloid leukemia, multiple myeloma, myeloid cells, stromal cells, myeloid neoplasms, lymphoid malignancies
- MeSH terms
- Animals, Bone Marrow, Hematopoietic Stem Cells, Humans, Inflammation, Multiple Myeloma, Hematologic Neoplasms, Stem Cell Niche, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.